BioAmber (BIOA) Given News Sentiment Score of -0.03
News coverage about BioAmber (NYSE:BIOA) has been trending somewhat negative recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioAmber earned a news impact score of -0.03 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.4691288819914 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- BioAmber Inc. (BIOA) stock RSI 17.25 signaled a sell opportunity – Voice Of Analysts (analystsbuzz.com)
- BioAmber Inc. (NYSE:BIOA) Trading Volume Significantly Higher – Modern Readers (modernreaders.com)
- BioAmber Inc. (NYSE:BIOA) Stock Closed Much Lower Than Its 50 Day Average (highlightpress.com)
- Is BioAmber Inc (BIOA)’s Triple EMA Building Momentum? – Evergreen Caller (evergreencaller.com)
- BioAmber Inc. (NYSE:BIOA) Traded -71.3% Below Its 50 Day Moving Average – Modern Readers (modernreaders.com)
BioAmber (BIOA) traded down 22.7231% on Friday, reaching $0.3377. The company had a trading volume of 12,248,250 shares. BioAmber has a 1-year low of $0.32 and a 1-year high of $6.50. The firm’s market capitalization is $12.53 million. The company’s 50-day moving average price is $1.32 and its 200 day moving average price is $2.25.
BioAmber (NYSE:BIOA) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. The business had revenue of $4.12 million during the quarter, compared to analyst estimates of $4.09 million. BioAmber had a negative net margin of 221.82% and a negative return on equity of 56.55%. On average, equities analysts forecast that BioAmber will post ($0.58) EPS for the current year.
BIOA has been the subject of several recent research reports. ValuEngine upgraded BioAmber from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Zacks Investment Research lowered BioAmber from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Cowen and Company set a $3.00 price target on BioAmber and gave the stock a “hold” rating in a research report on Monday, July 17th.
TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/bioamber-bioa-given-news-sentiment-score-of-0-03/1536845.html.
BioAmber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for BioAmber Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAmber Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.